About
Biocartesian builds ARADIA™, a proprietary in situ DNA-imaging technology that links pooled genetic perturbations to single-cell imaging phenotypes. It sells full-service and modular optical pooled-screening, readout, and analysis services to biological discovery teams. Its differentiation is microscopy-native functional genomics combining pooled scale with image-rich, reusable cellular datasets.
Market
Biocartesian competes in research-use functional genomics, optical pooled screening, high-content cellular imaging, and spatial-biology tools and services. Its differentiation is the ARADIA™ workflow, which reads perturbation-associated DNA sequences directly inside cells and links pooled genetic perturbations to microscopy-based phenotypes, enabling scalable single-cell datasets for target discovery and mechanism-of-action research.
Biocartesian primarily serves biotech and pharmaceutical discovery teams, as well as specialized life-science research groups, working in functional genomics, cell biology, drug discovery, and spatial biology. The likely buyers are heads of discovery or functional-genomics scientists who need scalable, image-rich pooled screens; the available evidence does not specify a minimum company size.
At a Glance
Problem
Biocartesian addresses a bottleneck in discovery biology: connecting the identity of a genetic or other perturbation to the rich cellular phenotype it produces. The main use case is a microscopy-native functional-genomics screen that reveals visual, spatial, molecular, or live-cell consequences of perturbations, giving discovery teams a more informative view of cellular biology and potential drug-relevant mechanisms. The economic pain is that fully arrayed workflows carry substantial cost and logistics, while teams still need scalable ways to run larger perturbation screens.
Product / Service
Biocartesian combines pooled screening workflows with ARADIA™, its readout and analysis technology, to connect pooled genetic perturbations with single-cell imaging phenotypes. The company can execute an entire screen as a full-service partner or provide modular ARADIA readout and analysis, adapting the work to a customer's cell model, perturbation system, library, marker panel, reporter, treatment, or live-cell workflow.
The benefit is faster, more scalable microscopy-based screening and a reusable, cell-level imaging dataset that can be revisited as new hypotheses, markers, or phenotypic features emerge. This positions the service as an expert-led way to move from focused pilots to larger screens without the cost and operational burden of fully arrayed experiments.
Market
Biocartesian competes at the intersection of functional genomics, spatial biology, and high-content screening, with an apparent B2B biotechnology focus spanning diagnostics and drug discovery. Its distinguishing category is optical or microscopy-native pooled screening: using image-rich cellular phenotypes, rather than only conventional molecular readouts, to study perturbation effects. The available evidence does not name specific competitors, so a reliable direct-competitor list cannot be established from the research.
The company is listed as an active Summer 2024 Y Combinator company, and available funding information reports $500,000 raised from investors including Y Combinator and Bullock Capital. The evidence demonstrates early financing and market activity, but does not report revenue, customer count, or commercial scale; therefore, Biocartesian's precise revenue status cannot be determined from the available sources.
Founders & Leadership
Funding History
Y Combinator
Recent News
Biocartesian’s updated product site introduces ARADIA™, its proprietary technology for reading targeted DNA sequences in situ. The platform links pooled genetic perturbations to microscopy-based single-cell phenotypes for optical pooled screening.
Biocartesian was selected for the Science Center’s 11th Capital Readiness Program cohort, a five-day Philadelphia bootcamp for early-stage health technology companies. The announcement describes Biocartesian’s technology as combining novel chemistry and microscopy to generate molecular maps of diseased tissue.
Active Roles
0No active roles right now.
Get notified when they postBusiness Model
Biocartesian monetizes paid, project-based research engagements, offering complete optical pooled-screen execution or modular ARADIA™ readout and analysis to life-science customers. Its website directs prospects to project inquiries, while specific pricing is not publicly disclosed.